A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Ozarelix, in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH).

Trial Profile

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Ozarelix, in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 03 Dec 2013

At a glance

  • Drugs Ozarelix (Primary)
  • Indications Benign prostatic hyperplasia; Lower urinary tract symptoms
  • Focus Therapeutic Use
  • Sponsors Spectrum Pharmaceuticals
  • Most Recent Events

    • 05 Feb 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 18 Dec 2008 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 18 Dec 2008 Actual start date (Sep 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top